Fluvoxamine

Introduction Overview

Generic Name

fluvoxamine

Brand Name

Luvox, Luvox CR

Dosage Form

oral capsule, extended release (100 mg; 150 mg), oral tablet (100 mg; 25 mg; 50 mg)

Drug Class

Selective serotonin reuptake inhibitors (SSRIs)

Pharmacokinetics

Absorption:
Fluvoxamine is well absorbed following oral administration, with peak plasma concentrations typically occurring within 3 to 8 hours after ingestion. Immediate-release formulations typically achieve plasma peak concentrations faster, often within 3 to 4 hours, whereas extended-release capsules provide a slower and more prolonged absorption, with peak concentrations around 7 to 8 hours. Fluvoxamine's absolute bioavailability is approximately 50% due to first-pass hepatic metabolism. Food intake does not significantly affect the extent of absorption, though it may modify the rate, with delayed gastric emptying slightly prolonging the time to peak concentration. Clinical implications of its absorption profile indicate the utility of once or twice daily dosing schedules, optimized by extended-release formulations to improve adherence and maintain steady plasma levels.

Distribution:
Fluvoxamine exhibits moderate plasma protein binding, approximately 80%, predominantly to albumin. It distributes extensively into body tissues, including the brain, where it exerts its pharmacological effects. The apparent volume of distribution (Vd) ranges between 25 to 45 L/kg, indicating wide tissue penetration. Distribution is influenced by patient factors such as age and body composition; elderly patients may exhibit higher plasma concentrations due to decreased clearance. The drug readily crosses the blood-brain barrier and the placental barrier, which is significant for therapeutic action and safety considerations, especially during pregnancy. Fluvoxamine's capacity to penetrate the central nervous system is vital for its efficacy in treating obsessive-compulsive disorder and related psychiatric conditions.

Metabolism:
Fluvoxamine is extensively metabolized in the liver predominantly via cytochrome P450 enzymes, notably CYP1A2 and CYP2D6 isoforms. The drug undergoes oxidative demethylation and other Phase I reactions followed by Phase II conjugation pathways. Metabolism leads to several inactive metabolites, which are primarily eliminated renally. Genetic polymorphisms impacting CYP2D6 or CYP1A2 activity can alter fluvoxamine plasma levels, necessitating dose adjustments in certain populations. Co-administration with inhibitors or inducers of these enzymes can significantly change fluvoxamine metabolism, causing either toxicity or reduced efficacy. Clinical monitoring is essential when fluvoxamine is prescribed alongside other medications altering hepatic metabolism. Hepatic impairment may reduce clearance, heightening risk for adverse effects.

Elimination:
Fluvoxamine’s elimination half-life ranges from 15 to 26 hours in healthy adults, supporting once or twice daily dosing regimens. It is primarily eliminated via renal excretion of its inactive metabolites, with less than 5% of unchanged drug excreted in urine. Renal impairment does not drastically affect fluvoxamine clearance; however, hepatic dysfunction may prolong half-life significantly. Steady-state plasma concentrations are typically reached within 7 to 10 days of consistent dosing. Clinically, this elimination profile requires careful titration to avoid accumulation and toxicity, especially in patients with compromised liver function. Drug interactions affecting metabolism can lead to altered elimination kinetics. No significant biliary excretion is noted, and fluvoxamine does not undergo significant enterohepatic recirculation.

Dosage Forms

Available Dosage Forms:
- Oral capsule, extended release: 100 mg, 150 mg
- Oral tablet (immediate release): 25 mg, 50 mg, 100 mg

Dosages for Adults and Adolescents:
- Adults (OCD): Initial dose for immediate-release tablets is 50 mg once daily at bedtime; for extended-release capsules, initial dose is 100 mg once daily at bedtime.
- Maintenance dose ranges from 100 mg to 300 mg daily.
- Dose increments are typically 50 mg every 4 to 7 days as tolerated.
- Total daily doses exceeding 100 mg should be divided into two doses with the larger dose given at bedtime.
- Adolescents (8-11 years, OCD): Start with 25 mg once daily at bedtime, maintenance dose 25-200 mg daily, maximum 200 mg/day.
- Adolescents (11-17 years, OCD): Start with 25 mg once daily, maintenance dose 25-300 mg daily, maximum 300 mg/day.
- Pediatric doses are increased in 25 mg increments every 4 to 7 days as tolerated and divided into two doses if daily dose exceeds 50 mg.

Specific Patient Populations:
- Children aged 8 years and older with OCD are approved for treatment, with lower starting doses and titration schedules tailored to age and weight.
- Caution and dose adjustment are recommended in patients with hepatic impairment due to reduced metabolism and prolonged half-life.
- In elderly patients, lower initial doses and careful dose titration may be necessary based on tolerance and renal function.
- Extended-release formulations are favored for patients who may benefit from once daily dosing or to reduce gastrointestinal side effects.
- Pregnant and breastfeeding patients should only use fluvoxamine if the potential benefits justify the risks; clinical monitoring is warranted.
- Dose modifications may be necessary when co-administered with CYP450 interacting drugs to avoid toxicity or treatment failure.

Mechanism Of Action

Fluvoxamine principally functions as a selective serotonin reuptake inhibitor (SSRI). At the molecular level, fluvoxamine selectively inhibits the serotonin transporter (SERT) on presynaptic neurons, thereby preventing the reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into the presynaptic neuron. This inhibition significantly increases the synaptic concentration of serotonin, enhancing serotonergic neurotransmission, which is critical in modulating mood, anxiety, and compulsive behaviors.

At the cellular pathway level, augmented serotonin levels in the synaptic cleft stimulate postsynaptic 5-HT receptors such as 5-HT1A, 5-HT2A/C, leading to downstream intracellular signaling cascades that ultimately result in altered neurotransmitter release, gene expression, and neuronal plasticity. These changes contribute to alleviation of symptoms in obsessive-compulsive disorder and other anxiety-related conditions. Fluvoxamine’s effect on serotonin levels also impacts the hypothalamic-pituitary-adrenal (HPA) axis, potentially normalizing the stress response.

Biochemically, fluvoxamine exhibits high selectivity for SERT and minimal affinity for other neurotransmitter transporters such as those for norepinephrine or dopamine, and lacks significant affinity for receptors such as histaminergic, cholinergic, or adrenergic receptors. This selectivity minimizes many classical side effects seen with less selective antidepressants. Fluvoxamine also has affinity, though less potent, for sigma-1 receptors, which has been postulated to modulate neuroprotective and anti-inflammatory pathways, although the clinical relevance remains an active area of research.

Clinically, fluvoxamine’s mechanism permits its efficacy in obsessive-compulsive disorder by reducing pathological serotonin dysregulation implicated in compulsions and obsessions. Comparative to other SSRIs like sertraline or paroxetine, fluvoxamine’s rapid uptake inhibition and specific receptor profile contribute to its particular therapeutic and side effect profile. Clinical studies demonstrate significant improvements in OCD symptom scales following chronic administration, supporting the drug’s modulation of serotonergic transmission as the primary mechanism. Ongoing research is exploring fluvoxamine's off-label potential, including adjunctive roles in neuropsychiatric and inflammatory disorders.

Pharmacological Actions

Selective inhibition of serotonin reuptake transporter (SERT) resulting in increased serotonin availability in the synaptic cleft.
Enhancement of serotonergic neurotransmission improving mood and alleviating anxiety and compulsive behaviors.
Modulation of postsynaptic serotonin receptor activation leading to downstream neuroplastic and gene expression changes.
Minimal activity on norepinephrine and dopamine transporters ensuring targeted serotonergic effects.
Partial agonist activity at sigma-1 receptors potentially providing neuroprotective and anti-inflammatory effects.
Improves symptoms of obsessive-compulsive disorder by normalizing serotonin dysregulation.
Exhibits anxiolytic properties through enhancement of serotonergic pathways.
Reduces obsessive thoughts and compulsive actions by altering central nervous system neurotransmission.
Pharmacodynamic profile contributes to distinct side effect and drug interaction profiles compared to other SSRIs.

Therapeutic Or Clinical Uses

Treatment of Obsessive-Compulsive Disorder (OCD) in adults and children aged 8 years and older.
Management of anxiety and stress-related disorders, including social anxiety disorder (off-label in some regions).
Used to alleviate symptoms of depression in selective cases, although not primary indication.
Potential off-label usage in other psychiatric conditions such as panic disorder and body dysmorphic disorder.
Investigational uses include adjunct therapy in neuropsychiatric and inflammatory conditions.
Symptomatic treatment for obsessive thoughts and repetitive behaviors.
Utilized to improve quality of life and functioning impairments related to OCD.
May aid in regulating mood and reducing anxiety in patients with comorbid depressive disorders.
Useful in pediatric psychiatric populations for OCD with appropriate dosing and monitoring.
Part of pharmacologic strategies combining psychotherapy for comprehensive OCD management.

Side Or Adverse Effects

Drowsiness, fatigue, and dizziness especially during initial treatment phases.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and upset stomach.
Central nervous system effects such as anxiety exacerbation, agitation, insomnia, or restlessness.
Sexual dysfunction including decreased libido, delayed ejaculation, anorgasmia, and erectile difficulties.
Dry mouth, excessive yawning, sore throat, and sweating as common autonomic side effects.
Neuromuscular symptoms including tremors, increased muscle movements, and muscle pain.
Dermatologic reactions such as rash or photosensitivity.
Menstrual disturbances including heavy or irregular periods.
Rare but serious: serotonin syndrome characterized by agitation, hallucinations, sweating, shivering, muscle stiffness, and autonomic instability.
Hyponatremia especially in elderly or those on concomitant diuretics, presenting with headache, confusion, weakness.
Allergic reactions including skin rash, edema, and respiratory distress.
Potential for increased suicidal ideation especially in children, adolescents, and young adults during treatment initiation.
Seizure risk in susceptible individuals; contraindicated in patients with seizure disorders without close monitoring.
Weight changes, appetite fluctuations ranging from decreased appetite to weight loss.
Bruising or abnormal bleeding tendencies especially when combined with NSAIDs or anticoagulants.

Precautions

Caution in patients with a history of bipolar disorder due to risk of inducing mania or hypomania.
Monitor closely in patients with seizure disorders; avoid abrupt discontinuation to prevent withdrawal seizures.
Evaluate electrolyte levels periodically, particularly sodium, due to risk of hyponatremia.
Patients with hepatic or severe renal impairment require dose adjustment and careful monitoring.
Use cautiously in patients with cardiac disease, hypertension, or cerebrovascular disorders.
Assess risk-to-benefit ratio in pregnant or breastfeeding women due to potential fetal/neonatal effects.
Avoid abrupt cessation to prevent withdrawal symptoms such as agitation, sensory disturbances, or confusion.
Monitor for signs of serotonin syndrome when combined with other serotonergic agents.
Caution advised when combined with medications causing sedation or CNS depression.
Observe for behavioral changes and emergent suicidality especially in pediatric and adolescent patients.
Regular assessment of sexual function is advisable as some issues can be managed therapeutically.
Screen for glaucoma before initiation in susceptible individuals due to potential pupillary effects.
Educate patients about possible interference with tasks requiring alertness such as driving or operating machinery.
Avoid concomitant use with monoamine oxidase inhibitors (MAOIs) due to risk of serious interactions.
Consider dose modifications in elderly patients and those with low body weight.

Warnings

Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults during initial treatment period.
Do not start or stop fluvoxamine suddenly without medical supervision to avoid adverse withdrawal effects.
Concomitant use with monoamine oxidase inhibitors (MAOIs) within 14 days before or after fluvoxamine is contraindicated due to risk of serotonin syndrome or hypertensive crisis.
Potential for severe serotonin syndrome when used with other serotonergic drugs, including triptans, tramadol, and St. John's wort.
May cause hyponatremia, particularly in elderly or diuretic users; monitor serum electrolytes.
Risk of bleeding abnormalities including increased bruising especially when combined with NSAIDs or anticoagulants.
Use with caution in patients prone to seizures, as fluvoxamine may lower seizure threshold.
Pregnancy risk: potential for fetal harm; benefits and risks should be carefully weighed.
Avoid breastfeeding while on fluvoxamine as it may pass into breast milk and affect the infant.
Patients should be warned about drowsiness or impairment in alertness affecting activities such as driving.
Fluvoxamine may exacerbate mania in patients with bipolar disorder; monitor mood changes closely.
May cause abnormal heart rhythms or QT prolongation in predisposed individuals.
Gradual dose tapering recommended to prevent discontinuation syndrome.
Psychiatric adverse reactions including agitation, irritability, or activation syndrome may occur early in treatment.
Avoid alcohol consumption to prevent potentiation of CNS depressant effects.

Contraindication

Hypersensitivity to fluvoxamine or any formulation components.
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy due to risk of severe interactions.
Use with thioridazine, tizanidine, alosetron, or ramelteon due to potentially life-threatening interactions.
Patients with a known history of serotonin syndrome induced by serotonergic agents.
Severe hepatic impairment where metabolic clearance may be significantly impaired.
Use in combination with pimozide due to risk of cardiac arrhythmias (not specifically mentioned in raw data but a recognized contraindication among SSRIs).
Caution or avoidance in patients with bleeding diathesis where risk of hemorrhage is elevated.
Contraindicated in patients with uncontrolled epilepsy or seizure disorders without specialist oversight.
Known hypersensitivity to other selective serotonin reuptake inhibitors (cross-reactivity potential).
Patients with angle-closure glaucoma due to risk of pupillary dilation and increased intraocular pressure.

Drug Interactions

Concomitant use with monoamine oxidase inhibitors (MAOIs) contraindicated due to risk of serotonin syndrome or hypertensive crisis.
Interactions with thioridazine, tizanidine, alosetron, and ramelteon contraindicated as they may cause serious or life-threatening reactions.
Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19, which can increase plasma levels of drugs metabolized by these enzymes, such as theophylline and clozapine.
Increased risk of bleeding when combined with NSAIDs, aspirin, anticoagulants (warfarin, Coumadin, Jantoven), or antiplatelet agents.
May increase effects and toxicity of benzodiazepine sedatives like diazepam, clonazepam, and alprazolam via CYP450 inhibition.
Potential enhanced serotonergic effects with co-administration of other antidepressants, triptans, opioids (tramadol), or St. John's wort leading to serotonin syndrome.
Interaction with methadone leading to increased risk of opioid toxicity.
Possible increased serum concentrations of mexiletine and other antiarrhythmics with concurrent use.
Use with diuretics may increase risk of hyponatremia.
Co-administration with stimulant medications, migraine medications, or antipsychotic drugs requires monitoring for additive CNS or cardiovascular effects.
Potential interaction with herbal supplements such as St. John's wort amplifying serotonergic side effects.
Careful monitoring required when combined with lithium due to risk of neurotoxicity.
Fluvoxamine may increase plasma concentrations of tricyclic antidepressants, benzodiazepines, and beta blockers through CYP450 inhibition pathways.
Drug interactions may alter fluvoxamine metabolism leading to subtherapeutic effects or increased adverse reactions.
Not all possible interactions are known; thorough medication review is essential when initiating or discontinuing fluvoxamine.

Preparations Of The Drug

Immediate release oral tablets available in 25 mg, 50 mg, and 100 mg strengths.
Extended-release oral capsules formulated in 100 mg and 150 mg strengths for once-daily dosing.
Formulations should be swallowed whole and not crushed, chewed, or broken to maintain pharmacokinetic profile.
Luvox and Luvox CR are the proprietary brand preparations marketed in the US and internationally.
Dosage forms are designed to provide flexible titration schedules to optimize therapeutic outcomes.
Extended-release preparations aid in improving patient adherence by simplifying administration to once daily.
Tablets and capsules are packaged in blister packs or bottles with child-resistant caps.
Storage requirements include keeping formulations tightly closed at room temperature, away from moisture and heat.
Additional formulations or generic equivalents may be available depending on regulatory approvals.
Prepared as prescription-only medications ensuring controlled prescribing and dispensing.
Formulations do not contain significant excipients that interfere with drug absorption or tolerability.
Oral dosage forms facilitate administration in both adult and pediatric populations.
Preparation labeling includes clear instructions to aid adherence and proper administration techniques.
Pharmaceutical quality control ensures stability and potency of fluvoxamine across marketed preparations.
Extended-release capsules use specialized delivery systems to maintain steady drug plasma levels.